Resverlogix Thinks RVX-208 Can Succeed At Reducing Arterial Plaque Where Pfizer's Torcetrapib Failed

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".